Browsing: GLP1

Robin Wenzel, head of Wells Fargo Industry Insights, explains how GLP-1 semaglutides are reshaping the healthcare business

About 1 in 5 American adults has already tried a GLP-1 medication, and as costs come down, that number is expected to keep climbing. Drugs like Ozempic and Wegovy are topping health trends in 2026, and their reach is expanding beyond weight loss into treatments for heart disease, kidney disease, arthritis and even addiction

People who want to lose weight with a GLP-1 drug can choose from an ever-growing number of telehealth companies offering the medications online

Two of the world’s largest pharmaceutical companies are riding the wave of popularity of GLP-1 drugs, which have led to higher sales for Eli Lilly and Novo Nordisk being reported on Tuesday

NEW YORK, Aug 2 (Reuters) – Nora Nye, 58, is refreshing her wardrobe as she sizes down for the first time in over three decades after losing 80 pounds on weight-loss drug Mounjaro. Earlier this year, the Denver bankruptcy lawyer walked into a Macy’s and found herself overwhelmed

A new large-scale study found that people with type 2 diabetes who are taking GLP-1 medications may have a higher risk of hair loss

1 medications appear to be linked to a higher risk of hair loss for some patients, a new study suggests

PHILADELPHIA (WPVI) –GLP-1 medications have revolutionized weight loss, and they are now being used in many ways to tackle obesity

The GLP-1 and active nutrition category, in particular, can be further segmented into three sub-groups: products for GLP-1 users, GLP-1 adjacent products, and products for post-GLP-1 users

Many GLP-1 clinical trials are not tracking what patients are consuming, pointing to a gap in the weight-loss market. Nutrition Insight asks FrieslandCampina Ingredients, Probi, Roquette, and HTBA what this data gap means for nutrition industry innovators developing solutions for GLP-1 users today.